Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Scynexis Inc (SCYX)

Scynexis Inc (SCYX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,453
  • Shares Outstanding, K 9,881
  • Annual Sales, $ 120 K
  • Annual Income, $ -53,710 K
  • 60-Month Beta 1.70
  • Price/Sales 569.19
  • Price/Cash Flow N/A
  • Price/Book 10.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -1.10
  • Number of Estimates 1
  • High Estimate -1.10
  • Low Estimate -1.10
  • Prior Year -1.60
  • Growth Rate Est. (year over year) +31.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.59 +26.72%
on 07/17/20
7.60 -6.71%
on 07/23/20
-0.10 (-1.39%)
since 07/02/20
3-Month
5.59 +26.72%
on 07/17/20
9.60 -26.15%
on 05/12/20
-2.01 (-22.11%)
since 05/05/20
52-Week
5.00 +41.80%
on 03/18/20
14.40 -50.76%
on 11/04/19
-3.61 (-33.74%)
since 08/05/19

Most Recent Stories

More News
SCYNEXIS Reports Successful Completion of Pre-NDA Meetings with the FDA Regarding Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug resistant infections, today announced the successful completion...

SCYX : 7.09 (-0.56%)
SCYNEXIS Announces Four Posters Presented at ASM Microbe 2020 Highlighting the Potential Clinical Utility of Ibrexafungerp

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of four...

SCYX : 7.09 (-0.56%)
SCYNEXIS Announces One-for-Ten Reverse Stock Split

SCYNEXIS, Inc. (NASDAQ : SCYX) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of its issued and outstanding...

SCYX : 7.09 (-0.56%)
SCYNEXIS to Host A Key Opinion Leader Discussion on the Immediate Need in Treating Women with Vaginal Yeast Infections

Discussion will be conducted via Webcast Call on Tuesday, July 14 at 10am Eastern Time

SCYX : 7.09 (-0.56%)
Calyxt Announces Board Changes

Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, announced the appointment of current board member Yves Ribeill, Ph.D., as Chairman. This appointment coincides with Dr. Andre Choulika's decision...

CMVLF : 17.3100 (+4.09%)
SCYX : 7.09 (-0.56%)
CLXT : 4.63 (+1.76%)
To Fully Focus on Cellectis, Dr. Andre Choulika Retires From Calyxt's Board of Directors

Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS) - Andre Choulika, Ph.D., Cellectis' Chairman and CEO, announces that he will focus all his energy on Cellectis' development activities, and thus, announces...

CMVLF : 17.3100 (+4.09%)
SCYX : 7.09 (-0.56%)
CLLS : 17.78 (+3.01%)
SCYNEXIS to Present at the BIO Digital International Convention 2020

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, M.D.,...

SCYX : 7.09 (-0.56%)
SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the appointment of Jim Maffezzoli,...

SCYX : 7.09 (-0.56%)
Scynexis: 1Q Earnings Snapshot

JERSEY CITY, N.J. (AP) _ Scynexis Inc. (SCYX) on Monday reported a loss of $7 million in its first quarter.

SCYX : 7.09 (-0.56%)
SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update

EQNX::TICKER_START (NASDAQ:SCYX), EQNX::TICKER_END

SCYX : 7.09 (-0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade SCYX with:

Business Summary

SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening...

See More

Key Turning Points

2nd Resistance Point 7.22
1st Resistance Point 7.16
Last Price 7.09
1st Support Level 7.01
2nd Support Level 6.93

See More

52-Week High 14.40
Fibonacci 61.8% 10.81
Fibonacci 50% 9.70
Fibonacci 38.2% 8.59
Last Price 7.09
52-Week Low 5.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar